Page 6 - Dave Ricks News Today

Health care may be a real challenger to tech this year, a business that can actually grow faster than most of tech.

Eli Lilly has no plans to ease up on R&D spending. Meanwhile, Danaher continues to await an 'inflection point,' while GE Healthcare touts its AI opportunity.

The latest catalyst for Eli Lilly is a corporate decision more common in the retail and entertainment industries, not pharmaceuticals.

Eli Lilly is marking a year of momentum as they continue into the final phases of testing and trials of its latest drug they say will help millions of people who struggle with obesity.

Eli Lilly priced its new weight-loss drug Zepbound 20% lower than competitor Wegovy, an unusual move in the pharmaceutical world.

"The incumbent almost always wins," Jim Cramer said this week.

Zepbound, made by Eli Lilly, is the newest FDA-approved drug for weight loss. (It was previously a diabetes treatment known as Mounjaro.)

Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q3 2023 Earnings Call. At this time all participants are in a listen-only mode [Operator Instructions].

The case for owning Eli Lilly got stronger Thursday, as diabetes drug Mounjaro crossed $1 billion in quarterly sales for the first time.

LLY earnings call for the period ending September 30, 2023.